HC Wainwright Weighs in on Nuvectis Pharma Q1 Earnings

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Nuvectis Pharma in a research report issued to clients and investors on Tuesday, February 25th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.31) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.24) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($1.87) EPS and FY2028 earnings at ($2.24) EPS.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08).

Nuvectis Pharma Trading Down 0.3 %

Shares of NASDAQ:NVCT opened at $6.69 on Friday. The stock has a market capitalization of $129.26 million, a P/E ratio of -5.77 and a beta of 0.22. Nuvectis Pharma has a 1-year low of $4.44 and a 1-year high of $12.10. The business has a 50-day moving average price of $6.26 and a two-hundred day moving average price of $6.41.

Hedge Funds Weigh In On Nuvectis Pharma

Institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new position in shares of Nuvectis Pharma during the 4th quarter worth about $34,000. Nations Financial Group Inc. IA ADV acquired a new position in shares of Nuvectis Pharma in the 3rd quarter valued at approximately $63,000. Baxter Bros Inc. grew its position in shares of Nuvectis Pharma by 20.0% in the 4th quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock valued at $81,000 after purchasing an additional 2,500 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Nuvectis Pharma in the 4th quarter valued at approximately $103,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Nuvectis Pharma in the 4th quarter valued at approximately $135,000. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, major shareholder Marlio Charles Mosseri bought 17,000 shares of the firm’s stock in a transaction dated Friday, December 13th. The stock was bought at an average cost of $4.70 per share, for a total transaction of $79,900.00. Following the transaction, the insider now owns 2,612,000 shares of the company’s stock, valued at $12,276,400. This represents a 0.66 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders bought 261,500 shares of company stock valued at $1,300,825. 35.78% of the stock is currently owned by insiders.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.